PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.995 EUR | -1.16% |
|
-1.80% | -34.89% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-06-27
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.995
EUR
Average target price
7.05
EUR
Spread / Average Target
+135.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.89% | 19.73M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
- News PHAXIAM Therapeutics S.A.
- Health Care Stocks Support American Depositary Receipts of European Equities
